By Northern Peptides Staff | October 26, 2026
What has stroke prevention research demonstrated most clearly? Blood-pressure-related vascular injury is a major, modifiable contributor to stroke risk, and controlled trials show that reducing blood pressure in defined study populations can reduce stroke events. In the randomized SHEP trial reported in JAMA in 1991, 4,736 older participants with isolated systolic hypertension were studied; the active-treatment group experienced a 36% relative reduction in total stroke over the study period. This finding is one strong example, not a universal prediction for every person or an instruction to use a particular intervention.
World Stroke Day takes place on October 29. In advance of that observance, this research overview examines the biological mechanisms, risk-factor evidence, and major prevention trials behind the scientific literature. It addresses worldwide prevention findings rather than the separate Canadian research-landscape article scheduled for October 29. The discussion is educational and contains no consumer treatment or dosing instructions.
Table of contents
- Nine findings
- How strokes develop
- Risk-factor evidence
- Randomized trials
- Primary and secondary prevention
- Understanding effect sizes
- Emerging research questions
- Assessing claims
- Frequently asked questions
- References
Nine findings from stroke prevention research
In stroke prevention research, the strongest conclusions combine population observations with randomized clinical studies. Population studies identify factors associated with events; trials can test whether a defined intervention changes outcomes in eligible participants. Neither kind of evidence should be stretched beyond its methods or population.
| Finding | Evidence category | Scientific takeaway |
|---|---|---|
| 1. Blood pressure matters | Observational studies and trials | Sustained vascular pressure influences risk and is experimentally modifiable. |
| 2. Ischemic and hemorrhagic stroke differ | Vascular biology | The mechanisms and outcomes are not identical. |
| 3. Risk factors cluster | Multinational case-control research | Multiple exposures may contribute to the population burden. |
| 4. Primary prevention has trial evidence | SHEP randomized trial | Stroke rates decreased in a selected older hypertensive cohort. |
| 5. Recurrence can be studied separately | PROGRESS randomized trial | Stroke events fell in participants with previous stroke or TIA. |
| 6. Composite endpoints require care | SPRINT randomized trial | Cardiovascular benefit does not mean every component was independently proven lower. |
| 7. Relative risk is not absolute risk | Trial interpretation | A percentage reduction needs baseline-event context. |
| 8. Research populations matter | Evidence appraisal | Findings vary with eligibility and study design. |
| 9. Prevention is still evolving | Mechanistic and implementation research | Unanswered questions concern heterogeneity, access, adherence, and long-term outcomes. |
These findings make stroke prevention research more informative than an isolated headline percentage. A credible summary says what was measured, who was enrolled, how comparison groups differed, and how much uncertainty remains.
Transparent endpoint definitions help stroke prevention research remain understandable across disciplines.
Finding 1: blood pressure is a major vascular exposure
For stroke prevention research, blood pressure exerts mechanical force on vessel walls. Over time, elevated pressure can contribute to changes in vascular structure and function, including injury to small vessels and atherosclerotic processes. It relates to ischemic and hemorrhagic outcomes through mechanisms that are overlapping but not identical.
Research has examined both chronic exposure and the consequences of changing pressure under controlled conditions. The observational association is important, yet randomized outcome trials provide more direct evidence that interventions affecting the pressure pathway can change clinical event rates in selected groups.
In stroke prevention research, blood pressure is therefore both a biological mechanism and a tractable variable for rigorous experimental comparison. This does not make any trial’s target or therapy a universal instruction for readers.
That distinction separates stroke prevention research findings from individualized care decisions.
Finding 2: stroke is not one biological event
In stroke prevention research, an ischemic stroke involves interruption of blood supply to part of the brain, usually because an artery is blocked. A hemorrhagic stroke involves bleeding from a ruptured vessel. The categories have distinct mechanisms, and studies may report their outcomes separately or combine them under “total stroke.”
Ischemic events can have varied causes, including large-artery atherosclerosis, small-vessel disease, and emboli arising from the heart. Hemorrhagic events involve vessel rupture and bleeding, sometimes in the context of hypertension-related vessel changes or other structural pathology. These differences complicate blanket prevention claims.
Good stroke prevention research specifies whether its result concerns ischemic stroke, intracerebral hemorrhage, total stroke, transient ischemic attack, or a broader cardiovascular endpoint. Without that distinction, the reader cannot know exactly what changed.
Specific outcomes allow stroke prevention research to compare like with like.
Finding 3: modifiable factors appear in clusters
Within stroke prevention research, international observational projects have examined blood pressure, tobacco exposure, diabetes, lipid-related markers, activity, diet, body-fat distribution, and cardiac conditions. These factors can interact and co-occur, so observed associations are difficult to reduce to one simple cause.
A landmark in stroke prevention research, the multinational INTERSTROKE investigation, led by Martin O’Donnell and colleagues and published in The Lancet in 2016, included participants across 32 countries. It examined ten potentially modifiable factors and their association with acute stroke. Population-attributable risk estimates describe a modelled burden under assumptions, not the probability that an individual event had one identifiable cause.
Stroke prevention research uses these associations to prioritize hypotheses and understand population patterns. Trials and other causal evidence remain necessary before concluding that changing a particular exposure by a given amount will produce a specific outcome.
The contrast between association and intervention is central to stroke prevention research.
Finding 4: prevention before a first event is testable
In stroke prevention research on primary prevention, researchers enroll participants without the outcome of interest and study whether an intervention changes the incidence of a first event. Such trials can require lengthy follow-up because even high-risk groups may have relatively few events over short periods.
The Systolic Hypertension in the Elderly Program, or SHEP, is a landmark example. Its randomized comparison focused on older adults with isolated systolic hypertension and tested a structured antihypertensive strategy against placebo. The researchers reported both a relative reduction and an absolute difference in observed stroke outcomes.
In stroke prevention research, carefully defined inclusion criteria help distinguish a strong result in one population from a claim of universal effectiveness across ages, medical histories, and baseline risks.
Participant selection is therefore a visible part of stroke prevention research quality.
Finding 5: recurrence has a different evidence base
Secondary prevention concerns people who have already experienced a stroke or a transient ischemic attack. Their baseline event risk and underlying causes may differ from those in a primary-prevention cohort. Evidence should therefore be interpreted separately rather than blending first-event and recurrent-event rates.
The PROGRESS trial randomized 6,105 participants with prior stroke or transient ischemic attack. Over approximately four years, the group assigned to the studied blood-pressure-lowering strategy experienced fewer strokes than the placebo group: 307 versus 420 events, reported as a 28% relative risk reduction.
This is influential stroke prevention research because it directly measured recurrent stroke outcomes. It does not imply that the regimen applies to every person, that medication choices are interchangeable, or that non-trial readers should act on the result without clinical context.
Reporting event counts adds clarity to stroke prevention research discussions of recurrence.
Finding 6: composite endpoints must be unpacked
Stroke prevention research often examines cardiovascular trials that combine several outcomes to gain statistical power. SPRINT enrolled 9,361 adults with elevated cardiovascular risk, excluding people with diabetes and prior stroke at entry, and compared two blood-pressure treatment strategies. Its main endpoint combined several cardiovascular events rather than counting stroke alone.
The 2015 SPRINT report found annual primary-composite event rates of 1.65% versus 2.19%, corresponding to a hazard ratio of 0.75. It would be incorrect to describe this as proof of a 25% stroke-specific risk reduction, because the quoted endpoint is composite.
Careful stroke prevention research respects the difference between a primary trial endpoint and individual components. It also examines harms and eligibility rather than interpreting statistically significant benefit as a cost-free intervention.
Composite-outcome scrutiny is especially important in stroke prevention research summaries.
Finding 7: risk reduction needs a denominator
Relative reductions can look dramatic without describing the event rate. In SHEP, investigators reported a 36% relative reduction in total stroke and an estimated five-year absolute benefit of 30 events per 1,000 participants in the studied population. Those two descriptions convey different but compatible information.
An absolute difference makes the scale easier to understand; a relative estimate can make comparisons across studies useful when baseline rates differ. Neither should be stated without follow-up duration, outcome definition, and uncertainty. Risk reductions are not guarantees that any given event will be prevented.
The ability to distinguish effect measures is essential to stroke prevention research literacy. It prevents readers from mistakenly treating a relative percentage as the percentage of all participants who benefited.
Time horizon belongs alongside percentages in stroke prevention research reporting.
Finding 8: trial eligibility controls generalizability
Trials improve causal inference by comparing assigned groups, but eligibility rules matter. SHEP enrolled older participants with a specific hypertension pattern. PROGRESS focused on participants with prior cerebrovascular events. SPRINT studied a high-risk group without diabetes or prior stroke. These are meaningfully different research populations.
Differences in age, coexisting conditions, prior events, competing risks, follow-up, and measurement methods can influence event rates and the balance of benefits and harms. An intervention’s measured average effect in one study is not automatically its effect in an excluded group.
Strong stroke prevention research therefore reports who entered and who did not. External validity is part of evidence interpretation, not an afterthought.
Eligibility differences explain why stroke prevention research results are not universal prescriptions.
Finding 9: implementation and biology both matter
Even when an intervention has trial evidence, real-world prevention faces challenges in measurement, access, continuity, treatment tolerance, and follow-up. Trials usually operate with protocols and surveillance that differ from ordinary healthcare settings. Those differences can affect how well results translate to broad populations.
Biological research continues to explore vessel injury, inflammation, thrombosis, cardiac sources of embolism, and recovery-related pathways. These mechanisms provide targets for further experiments, but mechanistic plausibility alone cannot establish that a candidate intervention prevents strokes in humans.
Future stroke prevention research must combine sound biology with well-controlled outcome studies and transparent reporting of adverse events. A promising laboratory signal remains preliminary until supported by the relevant human evidence.
Measured clinical outcomes are the decisive test for many stroke prevention research hypotheses.
How strokes develop
The brain relies on continuous delivery of oxygen and nutrients through a complex arterial network. When blood flow becomes insufficient, tissue function can deteriorate. The timing, location, and duration of impaired perfusion affect the resulting injury. Bleeding introduces a different set of structural and pressure-related mechanisms.
Vessel walls consist of interacting cells and extracellular structures. Endothelial function, smooth-muscle responses, inflammatory processes, and coagulation pathways all have roles in vascular biology. Researchers study these processes using laboratory models, imaging, pathology, and human observational designs.
These investigations support stroke prevention research by identifying potential explanations for epidemiological patterns. For example, arterial pressure plausibly influences vessel-wall stress, while certain cardiac rhythm abnormalities can create conditions for embolic material to reach the brain.
Small-vessel and large-vessel disease
Small cerebral vessels may undergo structural changes associated with chronic vascular risk factors. Larger arteries can develop atherosclerotic lesions that narrow a vessel or contribute to thrombus formation. Both mechanisms can affect cerebral perfusion, yet their diagnostic definitions and studied outcomes are not identical.
The distinction matters when evaluating research articles. A trial focused on atherosclerotic events may not answer all questions about small-vessel injury or hemorrhage. Similarly, animal models that reproduce one vascular pathway may not capture every feature of human stroke.
For stroke prevention research, mechanistic specificity helps researchers develop testable hypotheses and avoid presenting all vascular events as biologically interchangeable.
Thrombosis, embolism, and vessel rupture
Thrombosis refers to clot formation within the vascular system, while embolism describes material traveling to another location and obstructing flow. A ruptured cerebral vessel causes hemorrhage rather than a clot-related blockage as the initiating event. Some risk factors influence multiple pathways, but the relative importance varies.
Research on coagulation, platelets, cardiac function, and vascular structure can clarify distinct mechanisms. These are complex research topics whose clinical implications depend on individual circumstances and well-established outcome evidence, not on general claims about an isolated compound.
Stroke prevention research benefits from separating these paths at the outset. Otherwise, a finding relevant to one kind of event may be mistakenly generalized to another.
What risk-factor research can and cannot tell us
Case-control studies compare people who experienced an outcome with people who did not. They can assess many candidate exposures across relatively large populations and identify patterns worth further investigation. Because exposure and selection biases remain possible, a case-control association is not equivalent to random assignment of an intervention.
INTERSTROKE provides a major example. Its international recruitment and standardized framework allowed O’Donnell and colleagues to compare potentially modifiable factors across diverse settings. The 2016 publication reported that ten common factors together accounted for a large modelled population-attributable fraction of strokes in the sampled populations.
That finding is valuable stroke prevention research, but it should not be rewritten as “90% of strokes are guaranteed preventable.” Population-attributable fractions rely on modelling assumptions, associations, exposure distributions, and possible overlap between factors. They do not establish individual causes or promise that all hypothetical changes are achievable.
Blood pressure in observational research
Hypertension is frequently associated with stroke risk, and INTERSTROKE found a particularly strong association for a history of hypertension or measured elevated pressure. The published comparison reported an odds ratio of approximately 2.98 for the defined exposure, with a 99% confidence interval of 2.72–3.28.
An odds ratio describes an association under the study design. It is not an absolute future-risk prediction for a particular person. Its magnitude should not be compared casually with a hazard ratio from a randomized trial because the estimands and study designs differ.
This is why stroke prevention research is strongest when observational findings are read together with randomized evidence. Convergent patterns increase confidence without erasing the limits of each study.
Smoking, metabolic factors, and activity
INTERSTROKE evaluated multiple factors, including smoking, diabetes, abdominal adiposity measures, lipid-related markers, physical activity, and diet. These observations provide a map of associations that can inform scientific priorities. They cannot, by themselves, tell a reader exactly how much changing any one factor will reduce their personal risk.
Confounding complicates interpretation because exposures tend to cluster. Physical activity, diet, healthcare access, and other determinants may correlate with one another. Researchers use statistical adjustment to reduce some confounding, but measurement error and unmeasured variables may remain.
High-quality stroke prevention research makes these design limits visible. It distinguishes associations, causal hypotheses, and effects proven in controlled experiments, rather than merging them into broad wellness promises.
Clear causal language strengthens stroke prevention research credibility.
What randomized prevention trials found
Randomization helps distribute known and unknown baseline factors between study groups, increasing confidence that an observed difference is connected to the assigned strategy. Still, trials are not perfect: adherence, missing outcomes, endpoint definitions, safety events, and early stopping all matter when interpreting results.
The following table uses the reported findings of named published studies. These are research summaries, not treatment recommendations or prescriptions. Different endpoints and populations mean the rows should not be treated as a head-to-head ranking of treatments.
| Study | Journal/year | Sample and population | Reported outcome |
|---|---|---|---|
| SHEP Cooperative Research Group | JAMA, 1991 | 4,736 adults aged 60+ with isolated systolic hypertension | 36% relative reduction in total stroke; five-year absolute benefit 30 per 1,000 |
| PROGRESS Collaborative Group | The Lancet, 2001 | 6,105 with prior stroke or TIA | Stroke in 307/3,051 active versus 420/3,054 placebo participants; 28% relative reduction |
| SPRINT Research Group | NEJM, 2015 | 9,361 higher cardiovascular-risk adults without diabetes | Primary composite cardiovascular endpoint 1.65% versus 2.19% per year, HR 0.75; not a stroke-specific estimate |
| O’Donnell and colleagues, INTERSTROKE | The Lancet, 2016 | Multinational observational case-control analysis across 32 countries | Identified major risk-factor associations; not an intervention trial |
SHEP: a landmark primary-prevention trial
Published in JAMA in 1991, SHEP randomized 4,736 older adults selected for isolated systolic hypertension. The study compared an active stepped-care antihypertensive program with placebo and reported the incidence of total stroke during follow-up. The central reported relative reduction was 36%.
The publication also described a five-year absolute benefit of about 30 fewer strokes per 1,000 participants in the investigated population. That is an especially useful way to show how a relative result relates to the observed baseline burden.
SHEP remains important in stroke prevention research because its endpoint was stroke itself, not merely a laboratory surrogate. Its strength is a randomized comparison in a defined older population; its limitation is that one enrolled group cannot represent every population.
PROGRESS: recurrent stroke as the measured outcome
The PROGRESS Collaborative Group reported a trial involving 6,105 people who had experienced a prior stroke or transient ischemic attack. Active and placebo groups were similar in size, with 3,051 and 3,054 participants respectively. The average follow-up was four years.
The investigators observed 307 stroke events in the active group and 420 in the placebo group, corresponding to a reported 28% relative reduction with a confidence interval of 17%–38%. This is a direct recurrent-stroke endpoint rather than a composite cardiovascular proxy.
For stroke prevention research, PROGRESS illustrates why secondary prevention deserves separate analysis. The underlying risk context differs, and the result cannot be transported mechanically to someone without prior stroke or TIA.
SPRINT: a valuable but frequently misquoted trial
The SPRINT Research Group’s 2015 New England Journal of Medicine report randomized 9,361 participants with elevated cardiovascular risk, without diabetes. The groups were assigned different blood-pressure treatment targets under the study protocol, and the trial was stopped early following a median 3.26 years of follow-up.
Its primary composite endpoint occurred at 1.65% per year in the intensive group versus 2.19% per year in the standard group, with a hazard ratio of 0.75 and 95% CI 0.64–0.89. These figures concern a composite endpoint, not stroke alone.
Accurate stroke prevention research should not turn SPRINT’s composite finding into an invented stroke-only statistic. It should also account for trial eligibility, adverse-event reporting, and the distinction between a treatment strategy and a single numerical target quoted outside its study context.
Primary versus secondary prevention
Primary prevention studies seek to reduce the probability of an initial event. Secondary prevention studies address recurrence after an event has already occurred. The distinction determines which participants are eligible, what baseline risk looks like, and how outcomes should be interpreted.
It can also affect study duration and statistical precision. Trials need enough observed events to distinguish real effects from random variation. When an event is relatively uncommon over the follow-up window, larger samples may be needed to estimate differences reliably.
For stroke prevention research, mixing populations without explanation can create deceptive comparisons. A larger absolute benefit in a higher-risk group does not necessarily mean that the underlying intervention is biologically stronger in every setting.
Etiology matters after an event
The biological cause of a prior event can influence recurrent-risk patterns. Large-artery disease, small-vessel processes, and cardioembolic mechanisms represent different research categories. Studies may target selected causes or examine mixed populations with planned subgroup analyses.
Subgroup findings are especially vulnerable to overinterpretation when there are few events or many comparisons. Exploratory differences can inform future studies, but they should not be presented as definitive effects without sufficient design and statistical support.
Good stroke prevention research specifies the event type, etiologic classification, entry criteria, and whether a subgroup question was prespecified. Clear methods matter more than an exciting subgroup headline.
How to read risk reductions correctly
Research communication commonly reports relative risk reduction, absolute risk reduction, odds ratios, hazard ratios, and confidence intervals. They do not all answer the same question. A reader should identify the measure before comparing results across articles.
| Measure | Interpretation | Key caution |
|---|---|---|
| Relative risk reduction | Proportional difference in outcome risk between compared groups | Does not reveal the starting event rate by itself |
| Absolute risk reduction | Difference in event probability across groups over a period | Requires a specified population and follow-up window |
| Odds ratio | Ratio of odds, often from case-control analyses | Is not necessarily equivalent to a risk ratio |
| Hazard ratio | Relative instantaneous event rates under a time-to-event model | May not equal a simple cumulative-risk ratio |
| Confidence interval | Range expressing statistical uncertainty under a model | Does not remove design bias or prove broad generalizability |
Stroke prevention research benefits from reporting absolute and relative effects where possible. For example, SHEP’s 30 events per 1,000 over five years provides context that the relative 36% alone cannot convey. Both figures are meaningful when their original population and follow-up period accompany them.
Why one large percentage may mislead
A statement such as “risk fell by 40%” sounds decisive but leaves essential questions unanswered. Was the outcome stroke, a composite, or a risk-factor biomarker? Did investigators count first or recurrent events? How large was the study, and how long did it run? Was the finding prespecified?
Without these details, the same percentage can represent dramatically different absolute differences. Likewise, a statistically significant comparison may coexist with clinically important harms or uncertainty about excluded populations.
Careful stroke prevention research communicates both confidence and boundaries. Evidence does not become weaker because its authors explain who was studied and what remains unknown.
Emerging questions and evidence gaps
In stroke prevention research, scientists continue to investigate how vascular inflammation, lipid processes, endothelial function, sleep, environmental exposures, and metabolic pathways influence cerebrovascular injury. A growing collection of laboratory findings can generate promising hypotheses, but a plausible mechanism is not the same as measured clinical prevention.
In stroke prevention research, animal models can reveal cellular pathways under controlled conditions. Observational human studies can suggest associations. Randomized trials with clinically meaningful outcomes are needed to determine whether a proposed prevention strategy actually changes event rates in a defined human population.
For stroke prevention research, this evidence hierarchy is particularly important whenever an experimental peptide, molecular pathway, or supplement is discussed. A biochemical signal or cellular observation does not establish that a substance prevents strokes, is authorized for such a use, or is appropriate for human administration.
Better endpoints and fairer representation
Future stroke prevention research studies can improve by separating ischemic from hemorrhagic events where appropriate, specifying stroke subtype, reporting adjudication methods, and including follow-up sufficiently long to observe meaningful outcomes. They should also represent diverse participant populations without losing clarity about eligibility.
Research access is uneven across the world, and conditions such as socioeconomic disadvantage can complicate the translation of trial findings. Implementation studies can examine whether evidence-based systems achieve similar performance outside tightly controlled trial settings, while keeping equity and data quality in view.
Reliable stroke prevention research also reports inconclusive outcomes. Selectively highlighting positive findings while omitting safety signals or null endpoints creates a distorted impression of the field.
Complete reporting helps future stroke prevention research avoid repeating unproductive experiments.
Distinguishing laboratory markers from clinical endpoints
A research paper might document a change in an inflammatory marker, clotting assay, or vascular-image measurement. Such measures can help examine mechanisms, but their relationship to stroke occurrence must be established rather than assumed. A surrogate improvement does not automatically translate to fewer clinical events.
SHEP and PROGRESS are instructive precisely because they counted strokes. SPRINT is informative about cardiovascular outcomes, while its composite measure must remain clearly labelled. The endpoint shapes the strength and scope of a conclusion.
That distinction keeps stroke prevention research anchored to real-world outcomes and avoids overstating preliminary findings.
A checklist for assessing prevention claims
Before accepting an eye-catching claim, use these questions to evaluate whether the underlying research supports it. This is a reading framework, not a personal health decision tool.
- What design? Was it randomized, prospective observational, case-control, mechanistic, or preclinical?
- How many participants? Are sample size and recruitment methods clearly reported?
- Which population? Do eligibility criteria describe prior stroke, age, and major exclusions?
- Which endpoint? Was stroke directly measured, or was the result a composite or surrogate?
- What comparator? Was there a contemporaneous control group and a clearly defined assignment?
- How large an effect? Are relative and absolute values, follow-up duration, and confidence intervals supplied?
- Which harms? Were adverse events and withdrawals evaluated rather than omitted?
- Can it be reproduced? Do independent studies support a similar conclusion in relevant populations?
- What remains unknown? Does the paper name limitations and avoid claims beyond the data?
This nine-question framework complements the nine scientific findings above. It turns stroke prevention research into an auditable conversation about methods and outcomes, not a collection of impressive numbers detached from their meaning.
Reproducible claims are the long-term foundation of stroke prevention research.
World Stroke Day highlights the urgency of reducing stroke-related harm. An evidence-first discussion can support that aim by identifying what trials have established, where observational evidence is informative, and why novel mechanisms need proper clinical validation.
The enduring lesson of stroke prevention research is that careful measurement and responsible interpretation matter as much as the headline result. Progress becomes credible when the published study can answer exactly which events changed, in whom, and with what uncertainty.
Frequently asked questions
What is the strongest finding from stroke prevention research?
Among the best-supported conclusions is that blood-pressure-related vascular risk is important and can be modified in defined clinical trial populations. SHEP reported a 36% relative reduction in total stroke among 4,736 older participants with isolated systolic hypertension. This is a study result, not an individualized prediction.
How is primary prevention different from secondary prevention?
Primary prevention studies seek to avoid a first event; secondary prevention studies study recurrence after stroke or transient ischemic attack. Their populations and baseline risks differ, so results should not be treated as interchangeable.
Did SPRINT demonstrate a 25% reduction in stroke alone?
No. The 2015 SPRINT result commonly summarized as a 25% relative reduction refers to its prespecified composite cardiovascular endpoint, not stroke alone. Its stroke-specific component must be assessed separately rather than inferred from the composite result.
Does an INTERSTROKE population-attributable fraction mean an individual stroke was preventable?
No. Such fractions are modelled population estimates based on associations and assumptions. They cannot establish the cause of one person’s event or guarantee that changing an exposure would have prevented it.
Can an experimental peptide be said to prevent stroke based on laboratory mechanisms?
No. A cell or animal finding may justify further research, but human stroke-prevention claims require appropriate clinical outcomes and rigorous evidence. A proposed mechanism does not establish safety, efficacy, authorization, or suitability for human use.
References
- SHEP Cooperative Research Group. “Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: Final results of the Systolic Hypertension in the Elderly Program.” JAMA. 1991;265(24):3255–3264. 4,736 randomized; 36% total-stroke relative reduction; 30 events per 1,000 five-year absolute benefit. PubMed PMID 2046107. DOI: 10.1001/jama.1991.03460240051027.
- PROGRESS Collaborative Group. “Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack.” The Lancet. 2001. 6,105 randomized; 307 versus 420 stroke events; 28% relative reduction. PubMed PMID 11589932.
- SPRINT Research Group. “A Randomized Trial of Intensive versus Standard Blood-Pressure Control.” New England Journal of Medicine. 2015;373:2103–2116. 9,361 randomized; primary composite endpoint 1.65% versus 2.19% per year; HR 0.75. DOI: 10.1056/NEJMoa1511939. Published study.
- O’Donnell MJ, Chin SL, Rangarajan S, et al. “Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study.” The Lancet. 2016. 32 countries; elevated blood-pressure exposure OR 2.98 (99% CI 2.72–3.28). PubMed PMID 27431356.
- SPRINT Research Group. “Final Report of a Trial of Intensive versus Standard Blood-Pressure Control.” New England Journal of Medicine. 2021. Updated outcome adjudication and follow-up of the 9,361-person trial. PubMed PMID 34010531.
- World Stroke Organization. World Stroke Day 2026. Observance on October 29; 2026 campaign information. Official World Stroke Day page.
For laboratory research use only. Not for human consumption.
